Vorinostat and Palliative Radiotherapy

Phase 1CompletedNCT00455351

Oslo University Hospital15 enrolled

Overview

Phase I study. Side-effects when combined with standard palliative radiotherapy.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pelvic Cancer Radiotherapy

Interventions

VorinostatDRUG

Increasing dosing, phase I

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pelvic malignancy * Palliative radiation treatment planed * ECOG \<3 * Age\>18 years Exclusion Criteria: * Previous pelvic radiotherapy * Uncontrolled diarrhea * Insulin-dependent diabetes mellitus * BMI\<18.5

Locations (1)

The Norwegian Radium Hospital

Oslo, Norway

Outcomes

Primary Outcomes

DLT

Time frame: continously

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.